Home Newsfeeds Watching Globalstar; Traders Circulate Craig-Hallum Note With $5 Price Target

Watching Globalstar; Traders Circulate Craig-Hallum Note With $5 Price Target

https://rsh.craig-hallum.com/research/-/rf/d/ipreo/4005101569/1669127534/c28029ae-ea1f-4410-b967-bc7292ce80c7.pdf

byBenzinga Newsdesk

November 21, 2022

1 minute read

https://rsh.craig-hallum.com/research/-/rf/d/ipreo/4005101569/1669127534/c28029ae-ea1f-4410-b967-bc7292ce80c7.pdf

Goldman Sachs Initiates Coverage On PTC Therapeutics with Sell Rating, Announces Price Target of $35

By Benzinga Newsdesk

December 14, 8:28 AM

Goldman Sachs analyst Paul Choi initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Sell rating and announces Price Target of $35.

PTCT

Analyst Ratings

The Latest Analyst Ratings for Crown Castle

By Benzinga Insights

September 27, 12:00 PM

Crown Castle (NYSE:CCI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

CCI

West Pharmaceutical’s 2024 Outlook Cautious, Analysts Remain Optimistic

By Vandana Singh

February 15, 2:17 PM

West Pharmaceutical Services reports Q4 2023 adjusted EPS at $1.83, surpassing consensus. Quarterly sales hit $732 million missing estimates. 2024 guidance hints at moderated organic growth, emphasizing inventory management strategies.

WST

Evercore ISI Group Maintains Outperform on Inhibrx, Raises Price Target to $60

By Benzinga Newsdesk

October 5, 9:46 AM

Evercore ISI Group analyst Gavin Clark-Gartner maintains Inhibrx (NASDAQ:INBX) with a Outperform and raises the price target from $54 to $60.

INBX

Watching Globalstar; Traders Circulate Craig-Hallum Note With $5 Price Target

Related Posts

Goldman Sachs Initiates Coverage On PTC Therapeutics with Sell Rating, Announces Price Target of $35

The Latest Analyst Ratings for Crown Castle

West Pharmaceutical’s 2024 Outlook Cautious, Analysts Remain Optimistic

Evercore ISI Group Maintains Outperform on Inhibrx, Raises Price Target to $60